Zydus Wellness: Should You Buy, Hold, or Sell Right Now?
- September 4, 2026
- Posted by: Kunal Singla
- Category: Market
Zydus Wellness share price Rs 545.15 (NSE), roughly flat today. 52-week range Rs 367.55 to Rs 611.85. Q1 FY27 revenue up 66.8% YoY, profit down 7% YoY.
Quick Answer
Zydus Wellness Ltd share price is trading around Rs 545, roughly 11 percent below its 52-week high of Rs 611.85 but well above its 52-week low of Rs 367.55. Q1 FY27 revenue surged 66.8 percent year on year to Rs 1,440.8 crore, but net profit fell 7 percent to Rs 118.9 crore from Rs 127.9 crore a year earlier, a divergence likely tied to acquisition-related revenue additions carrying lower near-term margins. Full-year FY26 profit fell more sharply, down 43.2 percent to Rs 197.2 crore from Rs 346.9 crore in FY25. The stock trades at a rich 91 times earnings against a consumer wellness sector average near 35.7 times.
Zydus Wellness share price has pulled back from its 52-week high of Rs 611.85, and Zydus Wellness share price now trades near Rs 545 on the NSE, well above its 52-week low of Rs 367.55. With revenue surging but profit declining in Q1 FY27, investors are asking whether this consumer wellness products company is a stock to buy at the current level, a hold, or a sell given the rich valuation.
This Zydus Wellness stock analysis walks through the Q1 FY27 numbers, the divergence between revenue and profit growth, valuation against the consumer wellness sector, shareholding pattern and the technical setup, using figures sourced from company disclosures and public filings.
Click Here – Get Free Investment Predictions
About Zydus Wellness
Keep this backdrop in mind when reading the rest of this Zydus Wellness share price review. Before deciding on Zydus Wellness share price, it helps to understand the underlying business. Zydus Wellness Ltd. markets consumer wellness and health food products including well-known brands such as Complan, Glucon-D and Sugar Free, alongside skincare and other consumer health products, as part of the Zydus Group.
The very large jump in Q1 FY27 revenue, well beyond typical organic FMCG growth rates, suggests the addition of acquired or newly consolidated brands to the revenue base, which can carry different margin profiles than the company’s legacy portfolio and would help explain the divergence between strong revenue growth and declining profit.
Zydus Wellness Share Price Today: Key Levels
The table below summarises where Zydus Wellness share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Zydus Wellness CMP (NSE) | Rs 545.15 |
| Zydus Wellness CMP (BSE) | Rs 544.80 |
| 52-Week High | Rs 611.85 |
| 52-Week Low | Rs 367.55 |
| Market Capitalisation | Approximately Rs 17,133 crore |
Zydus Wellness share price is trading below its 52-week high, reflecting some market caution around the divergence between very strong revenue growth and declining profit in recent results.
Check the Univest Screener for Live Stock Data
Zydus Wellness Financial Performance
Track this line item closely if you are following Zydus Wellness share price closely. The Zydus Wellness share price trend is closely tied to how these numbers evolve each quarter. Zydus Wellness reported Q1 FY27 (June 2026 quarter) revenue of Rs 1,440.8 crore, up 66.8 percent year on year from Rs 863.9 crore, but net profit fell 7 percent year on year to Rs 118.9 crore from Rs 127.9 crore, a clear divergence between the topline and bottom line. This followed a volatile stretch that included losses in both the September and December 2025 quarters.
For the full year FY26, the company reported revenue of Rs 3,967.4 crore, up 45.7 percent year on year, with net profit of Rs 197.2 crore, down 43.2 percent from Rs 346.9 crore in FY25, confirming the pattern of strong revenue growth alongside declining profitability has persisted across the full year, not just one quarter.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Q1 FY27 (Jun 2026) | Rs 1,440.80 crore | Rs 118.90 crore | +66.8% revenue, profit -7% YoY |
| FY26 (full year) | Rs 3,967.40 crore | Rs 197.20 crore | +45.7% revenue, profit -43.2% YoY |
Valuation Check: Is Zydus Wellness Share Price Expensive?
It is one of the clearest signals available on Zydus Wellness share price today. Any view on Zydus Wellness share price should start from these valuation multiples. Zydus Wellness share price currently reflects a price to earnings ratio of about 91 times trailing earnings, a very steep premium to the broader consumer wellness sector average of roughly 35.7 times. The price to book ratio stands near 2.9 times, with return on equity at a modest 3.98 percent.
Debt to equity of 0.55 is moderate. Historically, consumer wellness companies undergoing revenue-accretive but margin-diluting acquisitions have traded at elevated PE multiples during the integration period, a pattern that appears consistent with Zydus Wellness’s current situation, though the very rich multiple leaves little room for further disappointment.
Technical Signals: What the Chart Shows
Price action here often foreshadows the next move in Zydus Wellness share price. Zydus Wellness share price is currently positioned about 11 percent below its 52-week high of Rs 611.85 and well above its 52-week low of Rs 367.55, reflecting a broadly positive run over the past year despite the recent profitability pressure. A stock trading here amid a revenue-profit divergence often reflects the market weighing the durability of the newly added revenue base against near-term margin dilution.
Trading volumes remain moderate, so investors should track Zydus Wellness share price alongside management commentary on margin recovery and the integration of newly added businesses in coming quarters, rather than reacting to any single day’s move at these technical levels.
Download the Univest iOS App or Univest Android App to track Zydus Wellness’ live price and technical levels.
Shareholding Pattern
Shifts here can influence Zydus Wellness share price more than headline news on some sessions. Zydus Wellness is part of the Zydus Group, a diversified Indian pharmaceutical and consumer healthcare conglomerate. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company’s latest exchange filing.
Why Investors Are Watching Zydus Wellness
- Very strong revenue growth: Q1 FY27 revenue surged 66.8 percent year on year, suggesting successful expansion of the company’s consumer wellness portfolio.
- Well-recognised consumer brands: Complan, Glucon-D and Sugar Free are established, trusted brands with long-standing consumer recognition in India.
- Strong Zydus Group backing: Being part of the Zydus Group provides institutional credibility and access to broader healthcare and consumer distribution capabilities.
- Potential for margin normalisation: If the profit pressure is tied to acquisition integration, margins could improve as newly added businesses are optimised over time.
Risks and Factors to Watch
- Sharp profit decline despite revenue surge: Full-year FY26 profit fell 43.2 percent even as revenue grew 45.7 percent, a significant divergence that needs to resolve favourably for the stock’s rich valuation to be justified.
- Very rich valuation: A 91x PE, a very steep premium to the consumer wellness sector, leaves essentially no room for further disappointment.
- Integration and margin dilution risk: If the revenue growth reflects newly consolidated businesses, successfully integrating and improving their margins carries execution risk.
- Consumer wellness sector competitive pressure: Zydus Wellness competes against large multinational and domestic FMCG companies across its consumer wellness categories.
Zydus Wellness Share Price Target: What the Data Suggests
Until then, Zydus Wellness share price remains best tracked through live, verified data rather than a single fixed number. Zydus Wellness does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time, given the unusual revenue-profit divergence in recent results. What the data shows is a company with very strong revenue growth but declining profitability, trading at a very rich premium to the sector.
Investors considering this stock should track the Univest Screener for management clarity on the margin trajectory, and should consult a SEBI-registered investment adviser given the very high valuation and unusual results pattern involved.
Zydus Wellness: Should You Buy, Hold, or Sell Right Now?
This is the core question behind Zydus Wellness share price right now. The Zydus Wellness buy or sell decision depends on whether you believe the profit-revenue divergence will resolve favourably.
The case for buying: Investors who believe the current margin pressure reflects temporary acquisition integration costs, and who trust the Zydus Group’s execution, may find the pullback from the 52-week high worth considering, provided they accept the very rich valuation.
The case for holding: Existing shareholders who already track Zydus Wellness’s brand portfolio may prefer to stay invested and watch for margin recovery signals.
The case for trimming or waiting: Investors uncomfortable with the very rich PE alongside declining profitability may prefer to wait for clearer confirmation of margin normalisation before committing fresh capital.
Given the unusual results pattern here, weigh this carefully and consult a SEBI-registered investment adviser if unsure.
Conclusion
Zydus Wellness share price reflects a consumer wellness company with very strong revenue growth but declining profitability across both Q1 FY27 and the full FY26 year, trading at a very rich premium to the sector below its 52-week high. Whether that makes the stock a buy, a hold or a sell right now depends on whether this revenue-profit divergence resolves favourably. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is Zydus Wellness a good stock to buy right now?
Ans. Zydus Wellness grew Q1 FY27 revenue 66.8 percent year on year, but profit fell 7 percent, a pattern also seen in FY26 where profit fell 43.2 percent despite 45.7 percent revenue growth. The stock trades at a very rich premium to the sector, so it suits investors who believe this margin pressure is temporary.
Q2. Why did Zydus Wellness’ profit fall despite strong revenue growth?
Ans. Zydus Wellness’ Q1 FY27 profit fell 7 percent year on year despite revenue surging 66.8 percent, a divergence that likely reflects newly acquired or consolidated businesses being added to the revenue base at lower near-term margins than the company’s legacy consumer wellness portfolio.
Q3. What is the Zydus Wellness share price today?
Ans. Zydus Wellness share price is trading around Rs 545 on the NSE. The stock’s 52-week high is Rs 611.85 and its 52-week low is Rs 367.55.
Q4. What is the Zydus Wellness share price target?
Ans. Zydus Wellness does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time, given the unusual revenue-profit divergence in recent results. Investors should consult a SEBI-registered adviser given the very high valuation involved.
Q5. What brands does Zydus Wellness own?
Ans. Zydus Wellness markets well-known consumer wellness and health food brands including Complan, Glucon-D and Sugar Free, alongside skincare and other consumer health products, as part of the Zydus Group.
Q6. What is Zydus Wellness’ market capitalisation and PE ratio?
Ans. Zydus Wellness has a market capitalisation of approximately Rs 17,133 crore and trades at a price to earnings ratio of about 91 times, a very steep premium to the consumer wellness sector average PE of roughly 35.7 times.
